Capabilities · Partner network

International manufacturing, connected to Japan

Since 2026, our partnership with Gensenta, an Eczacıbaşı Healthcare company, extends our platform to sterile injectables and oral solid dose forms, supporting technology transfer and commercial supply for Japan and international markets.

Gensenta at a glance

Established scale. International reach.

Gensenta supplies pharmaceutical products across Europe, Asia, the Middle East and other international markets, within multiple regulatory frameworks.

100+ years

pharmaceutical manufacturing heritage

~600 employees

across the organization

18+ markets

international supply experience

PMDA inspected

commercially supplying products to Japan

Figures on this page describe Gensenta’s platform. Capacity availability and product suitability are confirmed for each project.

The partnership

A broader platform. A clear local interface.

Manufacturing partner · Türkiye

Gensenta

Performs the sterile injectable and oral solid dose manufacturing, supported by a long international supply history and regulatory experience across multiple markets.

Your interface in Japan

Fujimino Pharma

Coordinates the agreed Japan-side requirements, technical interfaces and local supply activities, with technology-transfer experience and an operating presence in Japan.

Tatsuya Suekuni
Successful international manufacturing depends on more than technical capability alone. Quality alignment, clear communication and disciplined execution need to work across organizations and markets from the beginning.
Tatsuya Suekuni Senior Executive Officer, Fujimino Pharma

Manufacturing scope

Sterile injectables.

Aseptic fill-finish: established commercial sterile manufacturing on multiple vial-filling and lyophilization platforms.

3 established vial lines

~39,000 vials/hour combined filling capacity.

6 freeze dryers

~168 m² lyophilization capacity on the established lines.

24,000 vials/hour

New Annex 1-compliant isolator line for liquid and lyophilized products, with 38.7 m² lyophilization capacity.

300 / 1,000 L

Commercial formulation scales on the new platform.

The new aseptic isolator platform supports clinical and commercial manufacture of liquid and lyophilized vial products in accordance with current EU GMP Annex 1 requirements.

Manufacturing scope

Oral solid dose manufacturing.

Tablets and capsules: integrated commercial manufacturing from dispensing and granulation through compression, coating, capsule filling and packaging.

750 million tablets/year

installed tablet manufacturing capacity

160 million capsules/year

installed capsule manufacturing capacity

Integrated manufacturing

  1. Granulation
  2. Blending
  3. Tableting
  4. Coating
  5. Capsule filling
  6. Packaging

Development support

Analytical method developmentFormulation developmentCMC supportScale-upStability activities

Japan readiness

Consider the market from the beginning.

A viable manufacturing process is only one part of a successful Japan program. The technical-transfer plan and the Japan regulatory pathway develop in parallel, not in sequence.

Technical & analytical requirements

  • Comparability and validation requirements
  • Analytical-method and specification transfer
  • Stability commitments

Regulatory & quality interfaces

  • Dossier and marketing-authorization status
  • Required manufacturing-site changes
  • Importation and release model

Packaging & local supply

  • Japan-market packaging and artwork
  • Visual-inspection requirements
  • Storage and distribution temperatures
  • Forecast volumes and launch timing